On August 7, 2025 LaNova Medicines Ltd. reported that its internally developed CEACAM5/4-1BB bispecific antibody, LM-24C5, has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China to initiate a Phase II clinical trial (Press release, LaNova Medicines, AUG 7, 2025, View Source [SID1234656022]). The trial will evaluate LM-24C5 in combination with other anti-tumor agents in patients with CEACAM5-positive advanced solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) is highly expressed in various solid tumors—including non-small cell lung cancer, colorectal cancer, and gastric cancer—making it a promising target for cancer therapy[1]. LM-24C5 is a conditionally activated bispecific antibody engineered using LaNova’s proprietary 4-1BB agonist platform. It is designed to simultaneously bind CEACAM5 on tumor cells and 4-1BB on immune cells, thereby directing and activating immune responses within the tumor microenvironment while minimizing off-target immune activation and associated systemic toxicities.

Preclinical studies have demonstrated that LM-24C5 can induce durable anti-tumor immune memory and exhibits synergistic effects when used in combination with other immunotherapeutic agents. These results support its potential to become a first-in-class immunotherapy.

LM-24C5 is currently in Phase I/II clinical development in the United States.